Skip to main content
Novonesis AS logo

Novonesis AS — Investor Relations & Filings

Ticker · NSIS ISIN · DK0060336014 LEI · 529900T6WNZXD2R3JW38 CO Manufacturing
Open in API
Filings indexed 2,308 across all filing types
Latest filing 2013-02-01 Regulatory Filings
Country DK Denmark
Listing CO NSIS

About Novonesis AS

https://www.novozymes.com/en

Novonesis is a global biosolutions company formed through the combination of Novozymes and Chr. Hansen. The company develops and produces a broad portfolio of biological solutions, including industrial enzymes, functional proteins, and microorganisms such as cultures, probiotics, and yeast. Its products are utilized in over 30 industries to improve efficiency, sustainability, and product quality. Key markets include food and beverage, where solutions enhance nutrition and reduce waste; human and animal health; agriculture, promoting higher crop yields and animal welfare; and household care, for more effective cleaning. Novonesis applies biotechnological principles to address global challenges in production and consumption, aiming to create more sustainable systems and products.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2013
Regulatory Filings
2013-02-01 Danish
AGM Information 2013
AGM Information Classification · 99% confidence The document is an invitation ('inviterer dig til selskabets ordinære generalforsamling') for the Annual General Meeting (AGM) of Novozymes A/S, scheduled for February 28, 2013. It details the agenda, which includes the board's report, approval of the audited annual report, dividend proposals, and election/re-election of board members and the auditor. It also provides extensive logistical information on registration, voting rights, and proxy procedures. This content directly corresponds to the materials distributed for an AGM. Therefore, the classification is AGM Information (AGM-R).
2013-02-01 English
M&A Activity 2013
M&A Activity Classification · 99% confidence The document details the acquisition of Iogen Bio-Products by Novozymes for a specific cash consideration and potential earn-outs. It discusses the strategic fit, the impact on sales growth, EBIT margin, and ROIC outlook for 2013, and the anticipated closing date. This content strongly indicates an announcement related to a significant corporate transaction, specifically a merger or acquisition (M&A). Based on the provided definitions, the 'M&A Activity (Code: TAR)' category is the most appropriate fit for an announcement detailing the terms and financial implications of an acquisition.
2013-01-31 English
M&A Activity 2013
M&A Activity Classification · 99% confidence The document text describes a specific corporate action: Novozymes' acquisition of Iogen Bio-Products for a specified price (67.5 million CAD plus earn-outs). It details the strategic fit, the assets acquired, and the expected financial impact (sales growth, operating profit, ROIC) for the fiscal year 2013. This content relates directly to changes in the company's structure, assets, and financing/investment activities, but it is not a standard periodic financial report (10-K, IR, ER) or a general regulatory announcement (RNS). Since it details a significant transaction involving capital structure/financing/investment, the most appropriate category is 'Capital/Financing Update' (CAP), as M&A activity (TAR) usually refers to takeover bids or merger proposals, whereas this is a clear acquisition of a business unit/assets. Given the focus on the financial implications of the purchase, CAP is the best fit among the provided options, although TAR is a close second. I will classify it as TAR (M&A Activity) as acquisitions are fundamentally M&A events, even if they are asset purchases.
2013-01-31 Danish
Report Publication Announcement 2013
Report Publication Announcement Classification · 98% confidence The document text is extremely short ("Læs hele rapporten i pdf format." which translates to "Read the full report in pdf format."). This text does not contain the content of a financial report but rather an instruction or announcement that a report exists elsewhere (likely attached or linked). According to Rule 2 (The 'Menu vs Meal' Rule), this strongly indicates a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS), as it is announcing the availability of a report rather than being the report itself. Since RPA is a specific category for announcing report publication, it is the most appropriate choice over the general RNS fallback.
2013-01-23 Danish
Annual Report 2012
Annual Report Classification · 100% confidence The document is titled 'The Novozymes Report 2012' and contains comprehensive sections including a letter from the CEO, key financial figures, consolidated income statements, balance sheets, cash flow statements, and notes to the accounts. It covers the full fiscal year 2012 and provides a detailed analysis of company performance, strategy, and governance. This matches the definition of an Annual Report (10-K). FY 2012
2013-01-23 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.